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Abstract
Background: In premenopausal women, treatment with direct oral factor Xa inhibi-
tors is associated with an increased risk of heavy menstrual bleeding (HMB) compared 
with vitamin K antagonists (VKA). Treatment with the direct oral thrombin inhibitor 
dabigatran appears to be associated with a reduced risk of HMB compared with VKA. 
These findings come from small observational studies or post hoc analyses of trials in 
which HMB was not a primary outcome. Use of tranexamic acid during the menstrual 
period may be effective in patients with HMB, but prospective data regarding effi-
cacy and safety in patients on anticoagulant treatment are lacking.
Rationale and Design: A direct comparison of a factor Xa inhibitor and a thrombin 
inhibitor with HMB as primary outcome, as well as an evaluation of the effects of add-
ing tranexamic acid in women with anticoagulant-associated HMB is highly relevant 
for clinical practice. The MEDEA study is a randomized, open-label, pragmatic clinical 
trial to evaluate management strategies in premenopausal women with HMB associ-
ated with factor Xa inhibitor therapy.
Outcomes: Women using factor Xa inhibitors with proven HMB, as assessed by a 
pictorial blood loss assessment chart (PBAC) score of >150, will be randomized to 
one of three study arms: (i) switch to dabigatran; (ii) continue factor Xa inhibitor with 
addition of tranexamic acid during the menstrual period; or (iii) continue factor Xa 
inhibitor without intervention. The primary outcome is the difference in PBAC score 
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Essentials
• Management of anticoagulant-associated heavy menstrual bleeding (HMB) varies in clinical practice.
• The MEDEA study aims to evaluate management strategies of HMB while on factor Xa inhibitors.
• We present the rationale of this randomized, open-label, pragmatic clinical trial.
• We highlight some important and unique features in the study design.
1  | INTRODUCTION
Anticoagulant treatment is associated with an increased risk of 
bleeding, and abnormal uterine bleeding may occur in up to 70% of 
premenopausal women using anticoagulants in therapeutic doses.1 
Abnormal uterine bleeding includes disturbances of frequency, 
regularity, and duration of menstrual periods and can present as 
heavy menstrual bleeding (HMB) or intermenstrual bleeding. HMB 
is the most common clinical presentation, with estimates up to 35% 
in the general population, and is defined as >80 mL blood loss per 
menstrual cycle or as clinically excessive menstrual blood loss that 
disturbs the physical, emotional, social, or material quality of life.2
Direct oral anticoagulants (DOACs)—that is, the factor Xa in-
hibitors apixaban, edoxaban, and rivaroxaban, or the thrombin 
inhibitor dabigatran etexilate—are currently the preferred antico-
agulant compounds for the management of venous thromboembo-
lism (VTE) and atrial fibrillation (AF).3,4 The randomized controlled 
studies leading to their registration have shown a reduction in the 
incidence of major bleeding in DOAC-treated patients when com-
pared to patients treated with vitamin K antagonists (VKAs).5,6 In 
female VTE patients, however, treatment with factor Xa inhibitors 
has been associated with an increased risk of HMB when com-
pared to VKA-treated women. Previous case series and small 
cohort studies reported an increased intensity and duration of 
menstrual bleeding in young women treated with factor Xa inhibi-
tors.7-9 These findings were confirmed in post hoc analyses of the 
large randomized trials of the respective factor Xa inhibitors. The 
EINSTEIN studies and the HOKUSAI-VTE study reported higher 
10Department of Thrombosis and 
Haemostasis, Leiden University Medical 
Centre, Leiden, The Netherlands
11Department of Internal Medicine, 
Máxima Medical Centre, Veldhoven, The 
Netherlands
12Department of Internal Medicine, OLVG, 
Amsterdam, The Netherlands
13Department of Internal Medicine, 
Rijnstate Hospital, Arnhem, The 
Netherlands
14Department of Internal Medicine, Red 
Cross Hospital, Beverwijk, The Netherlands
15Department of Internal Medicine, Tergooi 
Hospital, Hilversum, The Netherlands
Correspondence
Eva N. Hamulyák, Department of Vascular 
Medicine, Amsterdam UMC, Amsterdam 
Cardiovascular Sciences, University of 




The MEDEA study is sponsored by 
Amsterdam UMC – location AMC, 
Department of Vascular Medicine. 
An unrestricted investigator-initiated 
research grant by Boehringer Ingelheim 
BV is gratefully acknowledged. Boehringer 
Ingelheim BV was not involved in the study 
design or in the preparation of the current 
manuscript.
Handling Editor: Neil Zakai
before and after randomization. Here, we present the rationale and highlight several 
unique features in the design of the study.
K E Y W O R D S
dabigatran, factor Xa inhibitors, menorrhagia, prospective studies, tranexamic acid
     |  225HAMULYÁK et AL.
rates of abnormal uterine bleeding for respectively rivaroxaban 
(hazard ratio, 2.1; 95% confidence interval [CI], 1.6-2.9) and edox-
aban (hazard ratio, 1.9; 95% CI, 1.1-2.5) in comparison with VKA-
treated women.10,11 In the AMPLIFY trial, the rate of abnormal 
uterine bleeding did not differ between apixaban and VKA (odds 
ratio [OR], 1.2; 95% CI, 0.7-2.0), but clinically relevant nonmajor 
bleeding was more likely of vaginal origin in apixaban-treated 
women.12 Remarkably, a post hoc analysis of the VTE trials with 
dabigatran reported that treatment with dabigatran appears to 
be associated with a lower risk of abnormal uterine bleeding than 
VKA (OR, 0.6; 95% CI, 0.4–0.9).13
HMB is chronic in nature and can have a major impact on quality 
of life, particularly in women requiring long-term anticoagulant ther-
apy.14,15 Suggested management options for anticoagulation-associ-
ated HMB include modification of type and dose of anticoagulant 
therapy, addition of tranexamic acid during menstrual periods, or 
hormonal therapy.16 Based on the post hoc analyses, it is important 
to investigate whether a switch from a factor Xa inhibitor to dabig-
atran may be beneficial in women with HMB. A direct comparison 
between factor Xa inhibitors and the thrombin inhibitor dabigatran, 
as well as the efficacy of adding tranexamic acid to reduce HMB, are 
needed to guide clinical decision making.
2  | STUDY OVERVIEW
2.1 | Design and study procedures
The MEDEA study is a multicenter, three-arm randomized, open-
label clinical trial in women with HMB on factor Xa inhibitor treat-
ment. A switch to dabigatran, addition of tranexamic acid to factor 
Xa inhibitor treatment during the menstrual period, and continuation 
of factor Xa inhibitor treatment without intervention will be evalu-
ated, with each woman serving as her own control before and after 
randomization.
The study is largely incorporated in routine clinical care of pa-
tients with anticoagulant-associated HMB, aiming for a pragmatic 
clinical trial. Potentially eligible subjects have a screening visit for 
a diagnostic workup and follow-up of HMB (T0). This workup in-
cludes an assessment of medical and gynecological history, including 
presence of HMB before initiation of anticoagulation, venous blood 
collection to evaluate presence of anemia, thrombocytopenia, liver 
or renal function impairment, and coagulopathy. Treatment of any 
other potential underlying disorder or concomitant disease, for in-
stance, iron deficiency anemia, is at the discretion of the treating 
physician and not part of study procedures. Referral to a gynecolo-
gist for a detailed workup is optional and also at the discretion of the 
treating physician, since this is not standard practice in all hospitals. 
After informed consent, participants are followed for one menstrual 
cycle without intervention to prospectively document HMB using 
the pictorial blood loss assessment chart (PBAC), that is, the base-
line PBAC score.17,18 The PBAC is a simple clinical tool that has been 
validated as a semiobjective assessment of menstrual blood loss and 
pattern of menstrual cycle (Figure S1).17-20
After an eligibility check (T1), women can be enrolled and ran-
domized in the study in a 1:1:1 ratio to one of the three study arms 
Figure 1].
1. Switch from Xa inhibitor to dabigatran.
2. Continued treatment with Xa inhibitor continues as before, with 
addition of tranexamic acid 1000 mg three times a day on the first 
day of menstrual bleeding for 4 days.
3. Continued treatment with Xa inhibitor continues as before.
The randomization process is centralized through a web-based 
Good Clinical Practice approved tool, using random permuted blocks 
of varying size. The doses for the respective Xa inhibitors and dabig-
atran can be found in Table S1. The allocated study treatment will be 
continued for three menstrual cycles following randomization (T2, 
T3, T4). Laboratory assessments will be repeated at end of the study. 
During follow-up, participants are asked to complete the PBAC as-
sessment, a general quality-of-life assessment, and the disease-spe-
cific menstrual bleeding questionnaire (MBQ)21 (Table S2).
A noteworthy feature in the study’s design is the escape option 
offered to women initially allocated to the continued factor Xa in-
hibitor treatment. At the initial randomization to this arm, this group 
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is immediately randomly allocated to either of the two intervention 
arms as a possible escape option. The Xa inhibitor treatment has to 
be continued at least one menstrual cycle after randomization, but if 
thereafter study participants require or wish to receive an interven-
tion for HMB, this escape option can be offered. This allows for the 
crossover comparison, with each participant serving as her own con-
trol feature to maintain, albeit with more observations per participant.
Study participants are identified by the treating physician as 
women who present with the clinical problem of HMB. With currently 
12 participating study sites in the Netherlands and more interested 
sites awaiting approval, we plan to recruit the required number of 120 
women in approximately 2 years. This type of collaboration has proven 
to be extremely fruitful, exemplified by the success of the YEARS 
study (Netherlands Trial Registry number 5913) or the HighLow study 
(Netherlands Trial Registry number 3894). The study is embedded in 
the Dutch Thrombosis Network, and we aim for a close collaboration 
between the departments of Vascular Medicine and Gynecology and 
Obstetrics within the participating centers to recruit participants.
2.2 | Study population and eligibility
All premenopausal women, aged ≥ 18 years at randomization treated 
with a factor Xa inhibitor in any dose for any indication in whom 
HMB has occurred and who have one prospective PBAC score above 
150 are potentially eligible for the current study. Participants must 
have an indication for anticoagulant treatment of >3 months after 
study inclusion. We exclude women who started with hormonal 
therapy as a new intervention for HMB, women who are pregnant 
or currently planning for pregnancy, and women with cervical pre-
neoplastic lesions or active malignancy. Eligibility criteria are listed 
in Table 1.
3  | RATIONALE FOR INCLUDING PATIENTS 
WITH ANY INDICATION FOR FACTOR 
XA THERAPY
Factor Xa inhibitor therapy is prescribed for various indications, 
most commonly VTE and AF. HMB associated with factor Xa 
inhibitor therapy is observed in women with different indications for 
anticoagulant therapy, but the impact of HMB on quality of life pre-
sumably is similar. Therefore, any woman presenting with the clinical 
problem of HMB while on factor Xa inhibitor therapy, regardless of 
the indication, and who is expected to need long-term anticoagu-
lation, is potentially eligible for participation in the MEDEA study. 
Women with a new indication for factor Xa inhibitor therapy may 
experience an aggravation of menstrual bleeding in the first cycle 
following treatment initiation. If discontinuation of anticoagulant 
treatment is expected shortly, an intervention for HMB may not be 
needed. In patients with an indication for long-term anticoagula-
tion, continued presence of HMB can severely affect quality of life 
and requires appropriate management. As in the current study each 
woman serves as her own control, we defined an indication for an-
ticoagulant treatment of at least 3 months after inclusion into the 
study as a strict inclusion criterion. Although we expect the majority 
of our study population to receive anticoagulant therapy for (recur-
rent) VTE, we plan exploratory analyses to evaluate outcomes in 
women with other indications and different treatment durations and 
recently started versus long-term anticoagulant therapy.
Different dose regimens of all three factor Xa inhibitors are al-
lowed, as long as the clinical problem of HMB is present. The pos-
sibly diverse phenotype of bleeding with the respective factor Xa 
inhibitors and doses, as well as the large intraindividual variability of 
heavy menstrual bleeding, are accounted for as each woman serves 
as her own control.
3.1 | Study interventions
3.1.1 | Rationale for management strategies in a 
three-arm trial
Switch from factor Xa inhibitor treatment to thrombin inhibitor 
dabigatran
The safety and efficacy of dabigatran in treatment of VTE disease 
has been well established, and there is ample experience with this 
specific agent in clinical practice. As opposed to evidence from 
the post hoc analyses of the factor Xa inhibitor licensing trials, a 
TA B L E  1   Eligibility criteria
Inclusion criteria Exclusion criteria
– Premenopausal women
– Age ≥ 18 years
– Anticoagulant treatment with a factor Xa inhibitor, either apixaban, 
edoxaban, or rivaroxaban
– Indication for anticoagulant treatment > 3 months after inclusion
– Heavy menstrual bleeding and a PBAC score > 150
– Use of adequate contraceptive methods during study participation 
(this is advised to any woman on factor Xa inhibitors during fertile 
ages, regardless of study participation)
– Concomitant use of hormonal therapy as a new intervention for 
heavy menstrual bleeding
– Pregnancy or currently planning for pregnancy
– Active malignancy or current treatment with chemotherapy, 
immunotherapy, and/or radiotherapy
– Cervical preneoplastic lesions
– Contraindication for the registered products dabigatran or 
tranexamic acid
– Any condition that, as judged by investigator, would place the subject 
at an increased risk of harm if she participated in the study
Abbreviation: PBAC, pictorial blood loss assessment chart.
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significantly lower risk of abnormal uterine bleeding in premenopau-
sal women with VTE treated with dabigatran compared with war-
farin (OR, 0.59; 95% CI, 0.39–0.90) was found in a recent post hoc 
analysis of the pooled RE-COVER-I, RE-COVER-II, and RE-MEDY 
trials.13 Anticoagulant-associated HMB may be reduced while on 
thrombin inhibitor compared with VKA, but a thrombin inhibitor has 
not been compared directly to a factor Xa inhibitor in this context. 
Although dabigatran appears to be associated with higher rates of 
hematuria and gastrointestinal hemorrhage compared with fac-
tor Xa inhibitors, the incidence of abnormal uterine bleeding may 
be lower.22,23 Observed differences among the different DOACs 
may be attributable to the post hoc nature of the evaluations and 
diversity in outcome assessment. However, there may be underly-
ing mechanistic explanations for a differential effect of dabigatran 
in comparison with factor Xa inhibitors. Local thrombin generation 
in the endometrium of the uterus is of great importance in the ces-
sation of menstrual bleeding, and it has been hypothesized that the 
capacity of standard dose dabigatran to inhibit thrombin may be lo-
cally exceeded by available thrombin. This allows for more local he-
mostatic action than warfarin, which continues to inhibit also higher 
thrombin levels, possibly explaining the observed rates in abnormal 
uterine bleeding between these two agents.24 The MEDEA study is 
the first randomized clinical trial directly comparing dabigatran and a 
factor Xa inhibitor with HMB as the primary study outcome.
Addition of tranexamic acid during menstrual period
Tranexamic acid, an antifibrinolytic agent, is safe and effective in 
reducing blood loss during the menstrual period in the general fe-
male population and women with bleeding disorders, but does not 
influence duration of bleeding.25,26 Tranexamic acid for this indica-
tion has never been evaluated in patients on anticoagulants. Current 
guidelines state active thromboembolic disease as a contraindica-
tion for treatment with tranexamic acid and recommend careful 
consideration before initiation of tranexamic acid in women with 
HMB and a history of VTE.27,28 Adverse events related to the use 
of tranexamic acid, including thrombosis, have been identified from 
postmarketing experience by the Food and Drug Administration, 
and the characteristics of this population are unknown.29 A recent 
meta-analysis including 22 randomized controlled trials with a total 
of 49 538 nonsurgical patients receiving tranexamic acid reported 
no increased risk of arterial or venous thrombosis.30
Tranexamic acid has been used in a variety of clinical and research 
settings, with good evidence of safety and efficacy during bleed-
ing in populations at high risk of VTE, including high-quality large 
randomized controlled trials involving patients with major trauma 
or severe postpartum hemorrhage.31,32 For women with a history 
of thrombosis, this is less certain, as they were excluded from the 
aforementioned trials. One previous nested case-control study of 
134 VTE cases and 552 matched controls did not find a statistically 
significant association between tranexamic acid and VTE risk, re-
porting an adjusted OR for VTE of 3.20 (95% CI, 0.65–15.78).33 With 
the available evidence of tranexamic acid use in other populations at 
high risk of VTE and considering that in the current study tranexamic 
is given in anticoagulated women, we do not expect an increased risk 
for participants randomized adding tranexamic acid during the men-
strual period. The MEDEA study will provide randomized evidence 
for the use of tranexamic acid as treatment of HMB in women with a 
history of thrombosis using factor Xa inhibitors.
The course of HMB associated with factor Xa inhibitor treatment
In the current study, one-third of the population continues the factor 
Xa inhibitor treatment without receiving an intervention for HMB. 
This control group serves to provide more insight in the course of 
HMB associated with factor Xa inhibitor treatment. In case the par-
ticipants allocated to the no-intervention group require or wish to 
receive treatment for HMB during the study, the escape option in 
the study design provides an opportunity to cross over to dabigatran 
or the addition of tranexamic acid.
3.2 | Study outcomes
The primary outcome is the difference in PBAC score before (T1) 
and the mean PBAC score after randomization (T2, T3, T4), with each 
woman serving as her own control. Several secondary outcomes will 
be assessed. The disease-specific MBQ is a validated patient-reported 
outcome measure for HMB.21 Quality of life will be assessed using 
this MBQ, in addition to a standardized 36-item short form survey. 
Duration of menses and occurrence of intermenstrual bleeding will 
be recorded in the electronic case report form, as well as a history of 
HMB before initiation of anticoagulation. An extensive evaluation of 
bleeding tendency is performed using the bleeding assessment tool 
of the International Society of Thrombosis and Hemostasis (ISTH) at 
inclusion.34 In patients referred to a gynecologist for further evalua-
tion, details of the gynecological workup are collected. Laboratory val-
ues, including hemoglobin and iron status, will be assessed at baseline 
(T1) and the end of the study (T4). Additionally, we will assess whether 
women who have had anticoagulant therapy for >6 months at the time 
of study inclusion experience different outcomes than women with a 
recent start of anticoagulant therapy, that is, <6 months.
During the study, any major, clinically relevant nonmajor and 
minor bleeding event other than HMB, as defined by the ISTH cri-
teria, will be reported as well as any event requiring an adjustment 
in anticoagulant treatment, for example, a new-onset thromboem-
bolic event while on anticoagulant treatment or interruption of an-
ticoagulant treatment before minor or major surgical procedures. 
New symptomatic thromboembolic events (either venous or arte-
rial) objectively confirmed by imaging will be recorded. All suspected 
clinical outcomes during the study period will be adjudicated by a 
committee blinded for treatment allocation. Adherence to the treat-
ment regimens is assessed using a patient diary specific to the study.
4  | RATIONALE FOR USE OF THE PBAC 
SCORE AS A STUDY OUTCOME
All available methods to measure menstrual blood loss have limi-
tations, but the PBAC is a simple clinical tool and has adequately 
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been validated as a semiobjective assessment of menstrual blood 
loss and pattern of menstrual cycle.17-20 In a cohort study of 429 
women who had previously participated in four prospective stud-
ies using PBAC as an outcome measure, the PBAC was found to 
have a low intraindividual variation.17 In the MEDEA study, the 
primary outcome is the PBAC score three menstrual cycles after 
randomization, with each woman serving as her own control. This 
aspect of the study reduces the required number of participants 
considerably, without putting statistical and clinical validity at 
risk.35
4.1 | Sample size considerations and 
statistical analysis
The study hypothesis is that either a switch from factor Xa inhibitor 
to dabigatran or addition of tranexamic acid during the menstrual 
period will decrease HMB, as objectively confirmed by a reduction 
in PBAC score. Each participant will serve as her own control. We 
assumed a PBAC score reduction of at least 25% to be clinically rele-
vant. To ensure an 80% power (β = 0.2) at a significance level of 0.05, 
approximately 34 women are needed to detect at least 25% reduc-
tion before and after intervention. Taking potential loss to follow-up 
into account, we settled on three groups of 40 women each.
The primary analysis will be the comparison in PBAC score be-
fore randomization (ie, while on factor Xa inhibitor [T1]) with the 
mean PBAC score after randomization (T2, T3, T4), reporting the 
paired differences before and after intervention with correspond-
ing 95% CIs per treatment group. Differences between treatment 
groups at three cycles after randomization will additionally be ex-
plored. Efficacy analyses will be based on the intention-to-treat prin-
ciple, including all patients who have received at least one dose of 
the allocated medication. Patients in the group that continues factor 
Xa inhibitor without intervention who opt for the escape option will 
be analyzed per protocol (ie, PBAC comparison before using the es-
cape option) and in a modified intention-to-treat analysis (ie, PBAC 
comparison before and after using the escape option). An additional 
analysis will be performed, excluding all study subjects who received 
any intervention for HMB in addition to the intervention assigned in 
the trial.
Secondary analyses will comprise the association between PBAC 
scores, laboratory values, and outcomes of the quality-of-life ques-
tionnaires in each study group at baseline (T1) and end of study (T4) 
(Table S2). Exploratory analyses based on the type, dose, and indica-
tion of DOAC are planned.
5  | COMEDICATION: HORMONAL 
THERAPIES AND MEDICATION 
AFFECTING HEMOSTASIS
Combined oral contraceptives are effective in reducing HMB and 
are frequently used for treatment thereof. A post hoc analysis of the 
EINSTEIN studies showed that hormonal therapy, estrogen-contain-
ing or progestin-only therapy, was not associated with an increased 
risk of recurrent VTE while on anticoagulant treatment with an ad-
justed hazard ratio of 0.56 (95% CI, 0.23-1.39).10
Levonorgestrel-containing intrauterine system (LNG-IUS) is also 
effective in reducing the amount and duration of menstrual blood 
loss and is safe in treatment of women receiving anticoagulants.36 
Initiation or switching of hormonal therapy, including combined oral 
contraception or an LNG-IUS, as a new intervention for HMB during 
study participation is not allowed. Newly started hormonal therapies 
would not allow estimation of the net effects of the studies’ thera-
pies and invalidate analyses and subsequent results.
Continuation of hormonal therapy while on anticoagulant treat-
ment is a reasonable option, as it is an adequate contraceptive 
method and sudden cessation may aggravate HMB even further. 
Nonsteroidal inflammatory drugs are commonly used to reduce 
menstrual blood loss and pain and affect hemostasis. The use of any 
medication that affects hemostasis, including antiplatelet therapy, is 
discouraged given the risk of increased bleeding while also on ther-
apeutically dosed anticoagulant therapy; chronic use, however, is 
allowed and carefully recorded.
6  | EXPECTED RESULTS AND 
FUTURE STEPS
The MEDEA study may change clinical practice in women with anti-
coagulation-associated HMB and aid the treating physician and the 
patient in choosing an optimal, evidence-based treatment strategy. 
This will be the first clinical trial involving a direct comparison of the 
thrombin inhibitor dabigatran and the respective factor Xa inhibi-
tors. The practically applicable PBAC score will be used as an identi-
fier of HMB and study end point. The trial interventions, crossover 
design and simple clinical tool to objectify HMB allow for a smooth 
implementation of the study in routine clinical care. If the trial re-
sults indicate dabigatran indeed to be associated with less HMB, this 
may support the use of dabigatran as preferred treatment option in 
women of reproductive age. Additionally, this trial will provide pro-
spective data on the effects of tranexamic acid in women with an in-
dication for anticoagulation. Although this strategy in treatment of 
HMB is applied in clinical practice by some, others are reluctant due 
to lack of evidence in the population of women with an indication for 
therapeutically dosed anticoagulation.
Possible next steps include lowering the age at study inclusion 
from 18 years to 12 years, thus allowing adolescents presenting with 
HMB while on factor Xa inhibitor treatment to participate in the trial 
as well. Both dabigatran and rivaroxaban were very recently evalu-
ated in the pediatric population in the DIVERSITY and EINSTEIN-Jr 
studies, with good efficacy and safety profiles in comparison with 
standard anticoagulation.37,38 Furthermore, the net benefit of dose 
reduction in women with HMB while on factor Xa inhibitor treat-
ment requires additional investigation, possibly in an extension of 
the current trial.
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In conclusion, the MEDEA study is a pragmatic clinical trial with 
the aim to optimize treatment of anticoagulation-associated HMB. 
Outcomes and experience attained from this study could provide 
groundwork for guidelines on anticoagulant treatment in women of 
reproductive age.
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